SecBot SecBot
SECBOTREPLAY Home › Report › TRVI

TRVI · Q3 net loss $21.5M

Trevi Therapeutics, Inc. · 8-K filed Nov 9, 2026 at 16:26 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 9, 2026 at 16:26 ET

Trevi Therapeutics reported a Q3 2026 net loss of $21.5 million, wider than the $11.8 million loss in Q3 2025, driven by increased R&D spending on Phase 3 OCEAN trials. The company highlighted FDA alignment on the non-IPF ILD program, initiation of the Phase 3 OCEAN-2 trial, and a USPTO Notice of Allowance extending patent protection to 2041. Cash runway into 2030 supports key milestones.

  • Q3 2026 net loss of $21.5 million vs $11.8 million in Q3 2025
  • Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026
  • Phase 3 OCEAN-2 trial initiated in Q3 2026; both OCEAN trials actively recruiting
  • Positive FDA meeting on non-IPF ILD program; Phase 2 dose-ranging trial expected Q1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access